| 1 |
33118660 | Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. | 2021 May |
2 |
| 2 |
31648367 | Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses. | 2020 Feb |
1 |
| 3 |
32208328 | Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. | 2020 Jun |
2 |
| 4 |
29343979 | The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. | 2018 |
1 |
| 5 |
29737183 | Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism. | 2018 Dec |
1 |
| 6 |
27738718 | Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. | 2017 Jan |
1 |
| 7 |
28787271 | Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. | 2017 Sep 26 |
4 |
| 8 |
26514968 | Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. | 2016 Feb |
2 |
| 9 |
27469576 | CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. | 2016 Aug |
4 |
| 10 |
27695358 | The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. | 2016 |
4 |
| 11 |
25868121 | The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. | 2015 Jun |
1 |
| 12 |
26639694 | CYP3A4 activity and haloperidol effects in alcohol addicts. | 2015 |
4 |
| 13 |
24739668 | Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. | 2014 Dec |
1 |
| 14 |
24088126 | Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. | 2013 Oct |
3 |
| 15 |
20491279 | [Clinical pharmacogenetics in the treatment of schizophrenia]. | 2010 Apr |
1 |
| 16 |
19817501 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | 2009 |
1 |
| 17 |
19902987 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. | 2009 |
2 |
| 18 |
17667795 | Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. | 2007 Aug |
3 |
| 19 |
16633141 | Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. | 2006 Apr |
6 |
| 20 |
16805946 | Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. | 2006 Jul |
1 |
| 21 |
16910628 | [Use of antidepressant drugs in schizophrenic patients with depression]. | 2006 Mar-Apr |
1 |
| 22 |
15572279 | Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. | 2005 Jan |
1 |
| 23 |
16045195 | [Clinical pharmacogenetics in the treatment of schizophrenia]. | 2005 Jun |
1 |
| 24 |
15048614 | Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. | 2004 Mar |
6 |
| 25 |
12657913 | Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. | 2003 Apr |
3 |
| 26 |
12691769 | Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. | 2003 May |
4 |
| 27 |
12746736 | Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. | 2003 |
1 |
| 28 |
12784098 | Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. | 2003 Aug |
18 |
| 29 |
12919180 | Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. | 2003 Sep |
3 |
| 30 |
12960748 | Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. | 2003 Sep |
2 |
| 31 |
14499311 | Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. | 2003 Sep |
3 |
| 32 |
12083975 | Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? | 2002 |
2 |
| 33 |
12107857 | Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. | 2002 May |
1 |
| 34 |
12362921 | Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. | 2002 Oct |
1 |
| 35 |
12386646 | The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. | 2002 Oct |
5 |
| 36 |
11167668 | Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. | 2001 Jan |
6 |
| 37 |
11477317 | Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. | 2001 Aug |
4 |
| 38 |
11560558 | Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. | 2001 Sep |
7 |
| 39 |
10688273 | Pharmacogenetics of classical and new antipsychotic drugs. | 2000 Feb |
1 |
| 40 |
10850389 | Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. | 2000 Jun |
1 |
| 41 |
10942177 | CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. | 2000 Aug |
2 |
| 42 |
10096261 | Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. | 1999 Mar |
2 |
| 43 |
10519444 | Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. | 1999 Oct |
1 |
| 44 |
10541779 | In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. | 1999 Oct |
6 |
| 45 |
10551545 | Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. | 1999 Sep |
4 |
| 46 |
10595685 | The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. | 1999 Oct |
2 |
| 47 |
10628896 | Pharmacokinetics of haloperidol: an update. | 1999 Dec |
3 |
| 48 |
9681669 | Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. | 1998 May |
7 |
| 49 |
9029745 | Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. | 1997 Feb |
1 |
| 50 |
9140699 | Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. | 1997 Apr |
2 |